Chapter 7 examines how international patient movements, inspired by organizations in the USA and Western Europe, have come to see ‘de-regulation’ as a way to accelerate the translation of science into marketable medical products. But in research abroad and an international meeting hosted in the UK, conversations with international patient organisation (health organisation) representatives for Muscular Dystrophy (MD) and Spinal Cord Injury (SCI) and patients from Asia, Europe and the USA shed different light on this. Discussions show that, in a world characterized by regulatory capitalism and inequality among countries, ‘de-regulation’ cannot ‘save’ patients through increased access to experimental medicine in the same way. For, the performance of regulation in a country is contingent upon the material and organisational resources available to health organisations and the population in general in a juridical mandate. The politics of redemptive regulation in international health movements risks reconfiguring healthcare developments by a misrecognition of actual patient needs and local practices. This chapter further raises questions about the potential benefits and costs of regenerative medicine to various patient groups in societies with different standards of wealth, welfare and political governance.